VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has been assigned a consensus rating of “Reduce” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $0.95.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd.

VistaGen Therapeutics Stock Performance

VTGN stock traded down $0.00 during trading on Monday, hitting $0.24. 106,702 shares of the company’s stock traded hands, compared to its average volume of 2,150,461. VistaGen Therapeutics has a 52 week low of $0.20 and a 52 week high of $5.14. The stock has a market capitalization of $10.65 million, a price-to-earnings ratio of -0.14 and a beta of 0.41. The business has a fifty day simple moving average of $0.34 and a 200 day simple moving average of $0.50.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. The firm had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. Research analysts forecast that VistaGen Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VTGN. Bank of America Corp DE raised its holdings in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after buying an additional 19,331 shares during the period. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics during the first quarter worth $25,000. Marshall Wace LLP purchased a new position in VistaGen Therapeutics during the second quarter worth $69,000. Jane Street Group LLC bought a new position in VistaGen Therapeutics during the second quarter valued at $190,000. Finally, Dimensional Fund Advisors LP increased its position in VistaGen Therapeutics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after acquiring an additional 24,655 shares during the last quarter. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.